# Kernal Biologics

Source: https://onco.cc/companies/kernal-biologics/  
OnCo record `kernal-biologics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kernal Bio designs mRNA medicines that switch on only in the intended cell type, for example programming a patient's T cells against cancer inside the body without taking them out first.

## Summary

Kernal Biologics develops cell-selective mRNA therapeutics: mRNA engineered to translate only in chosen cell types, delivered in lipid nanoparticles targeted to those cells. Its KR-402 programme uses T-cell-targeted particles to programme CAR-T cells in vivo and, per the company, achieves over 90 percent delivery efficiency with B-cell depletion within a week in preclinical models. Oncology applications include in vivo CAR-T and immune-stimulating mRNA for solid tumours. The company's YC profile names Hummingbird Ventures, Amgen Ventures, HBM and NASA among its backers; work is preclinical.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.kernalbio.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/kernal-biologics
- Official website: https://www.kernalbio.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Amgen Ventures](https://onco.cc/companies/amgen-ventures/), [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/kernal-biologics.json